Clinical trial
Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI…
NCT00139347 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00139347 |
|---|---|
| Title | Study of 2 Doses of HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants |
| Official title | A Multi-country & Multi-center Study to Assess the Efficacy, Immunogenicity & Safety of Two Doses of GSK Biologicals' Oral Live Attenuated HRV Vaccine Given Concomitantly With Routine EPI Vaccinations Including OPV in Healthy Infants |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Infections, Rotavirus |
| Intervention type | Biological |
| Interventions | 2-dose oral live attenuated G1P[8] human rotavirus vaccine |
| Enrollment | 6,360 |
| Start date | Dec 1, 2003 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Aug 31, 2005 |
| Last update posted | Oct 28, 2016 |
| Countries | Argentina, Brazil, Colombia, Dominican Republic, Honduras, Panama |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: